Friday, March 16, 2012

Interleukin-35 by Bettini at St. Judes

Title: Prevention of Autoimmune Diabetes by Ectopic Pancreatic β-Cell Expression of Interleukin-35

Quotes from Abstract:
Interleukin (IL)-35 is a newly identified inhibitory cytokine used by T regulatory cells to control T cell–driven immune responses. ...

Nonobese diabetic RIP-IL35 transgenic mice exhibited decreased islet infiltration with substantial reductions in the number of CD4+ and CD8+ T cells, and frequency of glucose-6-phosphatase catalytic subunit–related protein-specific CD8+ T cells. ...
[This] led to substantial, long-term protection against autoimmune diabetes ... 
These data present a proof of principle that IL-35 could be used as a potent inhibitor of autoimmune diabetes and implicate its potential therapeutic utility in the treatment of type 1 diabetes.


Saturday, March 10, 2012

CD40 inhibitory peptide by Wagner at University of Colorado


Wagner isolated the specific T-cells that attack the pancreas and cause most cases of Type 1 Diabetes. The research team has developed a drug that attacks those bad cells. 
It’s having an impressive effect on mice. The drug is not only preventing mice from developing diabetes, it’s also reversing the effects of diabetes in mice that already have the disease.

News article:

Related grant:
Related research:

Thursday, March 8, 2012

XMetA by Bhaskar at XOMA

XMetA is the first antibody specific for the insulin receptor shown to correct hyperglycemia in a mouse model of diabetes. Results of a study conducted by XOMA and confirmed by investigators at the University of California, San Francisco, demonstrate that XMetA has the potential to be a novel, long-acting agent for the control of blood glucose levels in patients with diabetes.
The study by Bhaskar, et al. demonstrated that XMetA markedly reduced elevated fasting blood glucose levels and normalized glucose tolerance in mice experimentally rendered diabetic. After six weeks of treatment, there was a statistically significant reduction in hemoglobin A1c levels in animals treated with XMetA compared to controls (p < 0.05). In addition, elevated non-HDL cholesterol levels were improved relative to control mice (p < 0.05). Hypoglycemia and weight gain were not observed during this study, nor was proliferation of cell growth.

Press Release: